168.84 -1.97 (-1.15%)
Pre-market: 8:01AM EDT
|Bid||169.20 x 800|
|Ask||169.66 x 1200|
|Day's range||158.21 - 171.92|
|52-week range||43.11 - 189.26|
|Beta (5Y monthly)||1.38|
|PE ratio (TTM)||N/A|
|Earnings date||06 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||175.58|
Moderna (NASDAQ: MRNA) beat Novavax (NASDAQ: NVAX) to market with a coronavirus vaccine. The U.S. Food and Drug Administration (FDA) authorized Moderna's candidate in December. Novavax expects to report U.S. phase 3 trial data in the coming weeks and complete an Emergency Use Authorization (EUA) request this quarter.
Italy has held talks with several manufacturers about starting production of mRNA-based Covid-19 vaccines in the country, in the latest sign that European officials want to deepen those supplies over other types of shot. Rome has discussed the domestic production of mRNA-based vaccines with US biotech Moderna, Switzerland’s Novartis and Italy’s ReiThera, people familiar with the matter said. The recent talks with Novartis and ReiThera included the possibility of producing the mRNA vaccine developed by Germany’s CureVac in Italy, two of the people said.
The Moderna jab, which works in a similar way to the Pfizer vaccine, uses synthetic messenger RNA (mRNA) technology that can be quickly tweaked to address new mutations of a virus.